Clinical interval and diagnostic characteristics in a cohort of bladder cancer patients in Spain: a multicenter observational study

Table 2 Time intervals and potential determinants

Hospital random effect empty model	Time interval between first consultation and first diagnosis					Time interval between diagnosis and first treatment
			Empty model ICC/MOR 0.05/1.47	95% CI MOR 1.14–3.06	P-value 0.037			Empty model ICC/MOR 0.26/2.81	95% CI MOR 1.56–11.06	P-value < 0.001
	Median (days)	IQR (days)	OR > 100 days	95% CI OR	P-value	Median (days)	IQR (days)	OR > 30 days	95% CI OR	P-value
Univariate regression
Gender
Male	104	113	1			0	366	1
Female	108.5	104	1.11	(0.58–2.10)	0.760	0	60	1.31	(0.44–3.87)	0.630
Age
< 65	104	105	1			0	203	1
≥ 65	107.5	114	0.99	(0.61–1.62)	0.976	0	366	0.99	(0.40–2.46)	0.984
BMI
< 25	90	99	1			0	364	1
≥ 25	110	116	1.39	(0.83–2.32)	0.211	0	366	0.39	(0.16–0.94)	0.037
Education level
Primary education or lower	102.5	107	1			0	366	1
Graduate school or higher	110	119	1.39	(0.86–2.24)	0.174	0	364	1.18	(0.49–2.85)	0.714
ECOG WHO score
Fully active	103.5	115	1			0	364	1
Restricted or worse	111	110	1.29	(0.80–2.06)	0.295	0	366	0.78	(0.32–1.91)	0.586
Specialist first consultation*
Primary care	115	116	1			0	364	1
Hospital or specialist	91.5	104	0.61	(0.38–0.97)	0.038	0	366	0.99	(0.41–2.41)	0.981
Primary tumour clinical stage^
T1	110	109.5	1			0	366	1
T2a–T4	102	120	0.78	(0.44–1.40)	0.404	0	364	4.39	(1.72–11.21)	0.002
Time since first symptom
Up to 1 month	56.5	103	1			0	366	1
More than 1 month	110.5	110	2.38	(1.25–4.51)	0.008	0	364	1.03	(0.32–3.34)	0.959

	Final model ICC/MOR	95% CI MOR	P-value	Final model ICC/MOR	95% CI MOR	P-value
Multivariate regression
Hospital random effect	0.05/1.48	1.12–3.78	0.078	0.29/3.06	1.63–13.1	< 0.001

BMI body mass index, IQR interquartile range, SD standard deviation, OR odds ratio, ICC intra-cluster correlation coefficient, MOR median odds ratio
* In the multivariate analysis to consult first Hospital or specialist shortened the time to diagnosis compared to consult Primary Care, OR 0.61 [0.38–0.97]
^{^}In the multivariate analysis the clinical stage T2a–T4 lengthened the time to treatment compared with clinical stage T1, OR 4.39 [1.72–11.21]

ISSN: 1756-0500